A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation

Hepatology

Volumn 27, Issue 5, 1998, Pages 1403-1407

  Gang, Edward J ^a   Lo, Su Kong ^a   Riordan, Stephen M ^a,b   Portmann, Bernard C ^a   Lau, Johnson Y N ^c   Naoumov, Nikolai V ^a,b   Williams, Roger ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CYCLOSPORIN A; PREDNISOLONE; RIBAVIRIN; TACROLIMUS; VIRUS RNA;

ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMOLYSIS; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; LEUKOPENIA; LIVER BIOPSY; LIVER TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; TREATMENT OUTCOME; VIREMIA;

ADULT; AGED; ASPARTATE AMINOTRANSFERASES; FEMALE; HEMOLYSIS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; RNA, VIRAL;

EID: 0031971088     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510270530     Document Type: Article

References (32)

1. Weinstein J, Poterucha J, Zein N, Wiesner R, Persing DH, Rakela J. Epidemiology and natural history of hepatitis C infection in liver transplant recipients. J Hepatol 1995;22:154-159.
2. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill J, Donaldson P, Maertens G, et al. Long-term outcome of hepatitis C infection after liver transplantation. N EngI J Med 1996;334:821-827.
3. Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC, Fiel I, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. HEPATOLOGY 1996;23:971-976.
4. Wright HJG, Van Thiel D. Preliminary experience with alpha 2-b interferon-α of viral hepatitis in liver allograft recipients. Transplantation 1992;53:121-124.
5. Wright T, Combs C, Kim M, Ferrell L, Bacchetti P, Ascher N, Roberts J, et al. Interferon-α therapy for hepatitis C virus infection after liver transplantation. HEPATOLOGY 1994;20:773-779.
6. Feray C, Samuel D, Gigou M, Paradis V, Reynes M, Bismuth H. An open trial of interferon-α recombinant for hepatitis C after liver transplantation. HEPATOLOGY 1995;22:1084-1089.
7. Di Bisceglie AM, Conjeevaram HA, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, et al. Ribavirin as therapy for chronic hepatitis C. Ann Intern Med 1995;123:897-903.
8. Gane E, Tibbs C, Ramage J, Portmann B, Williams R. Ribavirin therapy for hepatitis C infection following liver transplantation. Transplant Intern 1995;8:61-64.
9. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. HEPATOLOGY 1994;19:1513-1520.
10. Freese DK, Snover DC, Sharp H,. Gross CR, Savick SK, Payne WD. Chronic rejection after liver transplantation: a study of clinical, histopathological and immunological features. J Hepatol 1991;13:882-891.
11. Urdea MS, Horn T, Fulz TJ, Anderson M, Running JA, Hamren S, Ahle S. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucleic Acids Res Symp Ser 1991;24:197-200.
12. Davis GL, Lau JYN, Urdea MS, Neuwald PD, Wilber JC, Lindsay K, et al. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. HEPATOLOGY 1994;19:1337-1341.
13. Collins ML, Zayati C, Detmerr JJ. Preparation and characterisation of RNA standards for use in branched DNA hybridization assays. Ann Biochem 1995;226:120-129.
14. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 1986;5315:1575-1578.
15. Davis GL, Baiart LA, Schiff ER. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506.
16. Araya V, Dodson FS, Dvorchik I, Hung F, Demetris J, Rakela J. Efficacy and safety of alpha interferon for hepatitis C after liver transplantation [Abstract]. HEPATOLOGY 1996;24:295A.
17. Ning Q, Brown D, Paroda J, Cattral M, Fung L, Liu M, Rotstein O, et al. Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1 and procoagulant activity and preserves Thl cytokine production but inhibits Th2 cytokine response. [Abstract] HEPATOLOGY 1996;24:355A.
18. Patterson J, Fernandez-Larsson R. Molecular action of ribavirin. Rev Infect Dis 1990;12:1132-1146.
19. Sidwell RW, Hoffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad spectrum activity of virazole (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide). Science 1972;117:705-706.
20. Jolley W, Sharma B, Chami R, Ng C, Bullington R. Long-term skin allograft survival by combined therapy with suboptimal dose of cyclosporin and ribavirin. Transplant Proc 1988;20:703-706.
21. Bodenheimer HC, Lindsay KKL, Davis GL, Lewis JH, Thung SN, Mahaney K, Seef L. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicentre trial [Abstract]. HEPATOLOGY 1994;20:206A.
22. Fried M, Fong T, Swain M, Park Y, Beames M, Banks S, Hoofnagle J, et al. Therapy of chronic hepatitis B with a 6-month course of ribavirin. J Hepatol 1994;21:145-150
23. Hanafusa T, Ichikawa Y, Kyo M, Fukunishi T, Nagano S, Nakama K, Nishiuchi M, et al. Long-term impact of hepatitis virus infection on kidney transplant recipients and a pilot study of the effects of interferon alpha on chronic hepatitis C. Transplant Proc 1995;17:956-957.
24. Rostaing L, Izopet J, Baron E, Duffaut M, Fuel J, Durand D. Treatment of chronic hepatitis C with recombinant alpha 2b interferon in kidney transplant recipients: preliminary results and side effects. Transplant Proc 1995;27:948-950.
25. Durlik M, Rancewicz Z, Gaciong Z, Roewinska D, Nowaczyk M, Korczak-Kowalska G, Walecka-Zielecka B, et al. Treatment of chronic hepatitis B and C with interferon-α in renal allograft recipients: preliminary results. Transplant Int 1994;7:343-345.
26. Dousset B, Conti F, Houssin D, Calmus Y. Acute vanishing bile duct syndrome after interferon-α therapy for recurrent HCV infection in liver transplant recipients. N Engl J Med 1194;330:1160-1161.
27. Cheeseman SH, Rubin RH, Stewart JA, Tolkoff-Rubin NE, Cosimi AB, Cantell K, Gilbert J, et al. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation - effects on cytomegalovirus and herpes simplex virus infections. N Engl J Med 1979;300:1345-1349.
28. Lui SF, Ali AA, Grundy JE, Fernando ON, Griffiths PD, Sweny P. Double-blind, placebo-controlled trial of human lymphoblastoid interferon prophylaxis of cytomegalovirus infection in renal transplant recipients. Nephrol Dial Transplant 1992;7:1230-1237.
29. Mazzaferro V Regalia E, Pulvirenti A, Palazzo U, Andreola S, Pasquali M, Baratti D, et al. Effect of interferon and ribavirin prophylaxis after liver transplantation in HCV RNA positive patients [Abstract]. HEPATOLOGY 1995;22:287A.
30. Thevenot T, Mathurin P, Perrin M, Plassar F, Blot C, Opolon P, Poynard T. Side effects of ribavirin observed in 41 patients with chronic hepatitis C [Abstract). HEPATOLOGY 1996;24:396A.
31. Faure JL, Causse X, Bergeret A, Meyer F, Neidecker J, Paliard P. Cyclosporine induced hemolytic anemia in a liver transplant patient. Transplant Proc 1989;21:2242-2243.
32. Winkler M, Schulze F, Jost U, Ringe B, Pichlmayr R. Anaemia associated with FK 506 immunosuppression. Lancet 1993;341:1035-1036.